COUR Pharmaceuticals

Private

Skokie, IllinoisHealthcare & Life Scienceshttps://courpharma.com/

Last Round

Series B

Jun 18, 2026

Total Funding Raised

$155M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

COUR Pharmaceuticals is a clinical-stage biotechnology company that develops antigen-specific immune tolerance therapies to treat autoimmune and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immune tolerancenanoparticle therapyautoimmune disease treatmentbiotechantigen-specific therapyimmune-modifying therapynanomedicineclinical-stage biotechdrug pipelineType 1 diabetes treatmentmyasthenia gravis treatmentbiopharmaimmune reprogrammingCNPdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

COUR Pharmaceuticals Comps

Public and private peers based on sector, stage, and business model.

COUR Pharmaceuticals comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

COUR Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Jun 18, 2026
Series A	Jan 30, 2024
VC Round	Sep 7, 2022

View all Funding Rounds

Key People

Founding team and executive leadership

Brian Bock

CFO

Executive Team

COUR Pharmaceuticals Investors

Notable investors and investment history

COUR Pharmaceuticals investors
Investor	Rounds
Roche Venture Fund	Series A, Series B
Roche Venture Fund	Series A
Angelini Ventures	Series B, Series A
JDRF	Series A, Series B
Lumira Ventures	Series A, Series B
Pfizer	Series A
Chimera Capital Management	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jun 18, 2026
$50M round led by Lumira Ventures and Roche Venture Fund.

View all signals

COUR Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

COUR Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about COUR Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersSkokie, Illinois

Employee Range78

Year Founded2013

Last FundingJun 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.